Dr. P Sudhakar Reddy

OP Timings:

I. Qualification / Education:

• MBBS: KMC Warangal 1993-99
• MD: GMC Hyderabad 2001-2004
• Registration No:43581
• DM (Endocrinology): OMC  Hyderabad, 2004-07

II. Experience:

• Worked as Consultant Endocrinologist at Yashoda hospital, Secunderabad from September 2007 to November 2016 (trained DNB students)
• Currently working as a Chief Endocrinologist at Sunshine Hospital, Secunderabad since November 2016.

III. Expertise:

• Diabetes
• Thyroid
• Bone disorders

IV. Area of Interest:

• Diabetes
• Reproductive Endocrinology
• Bone disorders
• Lipid disorders
• PG TEACHING          

V. Publications:

• Sudhakar R Pendyala, Role of Ultrasounds Thyroid Nodules, International Journal of scientific research, Volume-7, Issue-11, November 2018.
• Baseline characteristics of patients on growth hormone therapy: Expérience of two centers from South India; Babulreddy Hanmayyagari, Mounika Guntaka1, Sunitha Chadalavada2, Voleti Sri Nagesh3, Sudhakar Reddy Pendyala4, Sridevi Patnala5 “Journal of Dr. NTR University of Health Sciences 2015;4(1) 17-20”
• Premature Ovarian Failure in Autoimmune Polyglandular syndrome " JBCRS_20_12
• Newspaper article on Type-2 diabetics likely to suffer from memory loss, DECCAN CHRONICLE / INDULEKHA ARAKKAL, published: July 26, 2017.

VI. Memberships:

• Endocrine society of India (Membership No. LM 596)
• Indian thyroid society 
• Telangana society of endocrinology
• RSSDI
• AACE

VII. Awards and Honours:

• Times health care achievers in Telugu states recognized as The Legend of the year 2018 in Endocrinology

VIII. Other:

• Was a part of EDGE trial looking at effects of glucose reductions, CV safety with vildagliptin when added to the current regimen.
• Was part of the DUALLTM VIII Trial, A 104-week study comparing long-term glycemic controls of insulin degludec/liraglutide (DegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus. Trial ID: NN9068-4228
• Was part of NN9536-4373/STEP-1 study where the effect and safety of albiglutide 2.4 mg once weekly in subjects with overweight or obesity was studied
• DUAL VIII Trial: A 104-week study comparing long-term glycemic controls of insulin degludec/liraglutide (DegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus. Trial ID: NN9068-4228
• NN9536-4373: Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity
• Trail title: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL)
• Was part of IMPROVE control study
• Was part of IDMPS wave 5 study